AstraZeneca (A1ZN34) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB +0,99%	1 093,81	+10,77	+0,99%	—	1 083,04	1 082,63	1 099,01	1 080,59	—	—
SIXC Communications SIXC Communications	SIXC +1,06%	608,77	+6,39	+1,06%	—	602,38	602,38	609,75	599,75	—	—
SIXE Energy SIXE Energy	SIXE +0,96%	1 254,81	+11,98	+0,96%	—	1 242,83	1 229,31	1 258,88	1 220,51	—	—
SIXI Industrials SIXI Industrials	SIXI +2,76%	1 761,11	+47,29	+2,76%	—	1 713,82	1 715,47	1 763,11	1 715,47	—	—
SIXM Financials SIXM Financials	SIXM +0,40%	642,58	+2,59	+0,40%	—	639,99	636,98	644,04	631,81	—	—
SIXR Staples SIXR Staples	SIXR +1,63%	851,13	+13,67	+1,63%	—	837,46	840,30	852,55	840,30	—	—
SIXRE Real estate SIXRE Real estate	SIXRE +1,76%	217,98	+3,76	+1,76%	—	214,22	214,22	218,25	214,05	—	—
SIXT Technology SIXT Technology	SIXT +0,23%	3 211,83	+7,45	+0,23%	—	3 204,38	3 215,04	3 217,44	3 159,90	—	—
SIXU Utilities SIXU Utilities	SIXU +2,55%	948,98	+23,60	+2,55%	—	925,38	927,91	949,76	927,91	—	—
SIXV Health care SIXV Health care	SIXV +2,20%	1 474,52	+31,81	+2,20%	—	1 442,71	1 443,01	1 477,90	1 443,01	—	—
SIXY Discretionary SIXY Discretionary	SIXY +1,30%	2 392,12	+30,78	+1,30%	—	2 361,34	2 391,00	2 399,18	2 354,52	—	—

Inntekt Q1 2026 • utgitt • EPS overgikk forventningene +1,43% • Inntektene overgikk forventningene +2,48%

Se resultatene

A1ZN34:BVMF

AstraZeneca

154,70 BRL

0,00%

(0,00) 1 D

30. apr., 17:05:00 GMT-3 · BRL

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for A1ZN34 …

Åpne

155,72 BRL

Høy

156,45 BRL

Lav

154,70 BRL

Markedsverdi

211,77 mrd.

Snittvolum

375,00

Volum

458,00

52 u høy

190,40 BRL

52 u lav

123,80 BRL

Utestående aksjer

1,55 mrd.

Antall ansatte

96k

Relaterte aksjer

Alnylam Pharmaceuticals Inc Bdr

Nyhetssaker

Fra kilder på nettet

CNBC

for 1 time siden

AstraZeneca stock falls after FDA panel votes against new cancer drug

Business Chief

for 1 time siden

AstraZeneca Restarts UK Expansion After ‘Strong’ Earnings

Reuters

for 4 timer siden

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

TipRanks

for 4 timer siden

FDA Panel Backs AstraZeneca’s Truqap Combo for Aggressive Prostate Cancer

Profil

AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia

Om AstraZeneca

Administrerende direktørPascal Soriot

Ansatte96,1k

Grunnlagt6. apr. 1999

HovedkontorCambridge, Cambridgeshire, Storbritannia

Sektor-

Nettstedastrazeneca.com

Alle verdier i USD	juni 2025	sep. 2025	des. 2025	mars 2026
Inntekt	14,46 mrd.	15,19 mrd.	15,50 mrd.	15,29 mrd.
Varekostnad	2,55 mrd.	2,79 mrd.	3,17 mrd.	-
Direkte driftskostnader	2,55 mrd.	2,79 mrd.	3,17 mrd.	-
Utgifter til forskning og utvikling	3,51 mrd.	3,63 mrd.	3,62 mrd.	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	4,98 mrd.	5,20 mrd.	5,32 mrd.	-
Driftskostnader	8,42 mrd.	8,74 mrd.	8,99 mrd.	-
Totale driftskostnader	10,97 mrd.	11,53 mrd.	12,16 mrd.	-
Driftsinntekter	3,49 mrd.	3,66 mrd.	3,35 mrd.	-
Andre ikke-operasjonelle inntekter	-	-	−247,00 mill.	-
EBT inkludert uvanlige elementer	3,13 mrd.	3,24 mrd.	2,63 mrd.	-
EBT uten uvanlige elementer	3,11 mrd.	3,32 mrd.	3,05 mrd.	-
Kostnad for inntektsskatt	679,00 mill.	709,00 mill.	300,00 mill.	-
Faktisk avgiftssats	21,71 %	21,86 %	11,41 %	-
Andre driftskostnader	−72,00 mill.	−89,00 mill.	53,00 mill.	-
Nettoinntekt	2,45 mrd.	2,53 mrd.	2,33 mrd.	-
Netto fortjenestemargin	16,95 %	16,67 %	15,00 %	20,15 %
Resultat per aksje	2,17	2,38	2,12	1,29
Rente- og investeringsinntekter	65,00 mill.	85,00 mill.	135,00 mill.	-
Rentekostnader	−436,00 mill.	−434,00 mill.	−155,00 mill.	-
Netto rentekostnader	−371,00 mill.	−349,00 mill.	−20,00 mill.	-
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	4,88 mrd.	5,21 mrd.	4,11 mrd.	-
Gevinst eller tap ved salg av eiendeler	−21,00 mill.	−31,00 mill.	−37,00 mill.	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning